MDI

Another insulin – October 2019

In the October update to the Australian PBS (Pharmaceutical Benefits Scheme), another insulin arrived today. Well, sort of. The addition is Semglee, which is a “biosimilar equivalent” to Lantus. Like Lantus it’s insulin glargine. Lantus is one of the commonly-used long-acting (or “basal”) insulin used for daily injections. It’s been around for years (I used …

Another insulin – October 2019 Read More »

D1_048789

Catching up with July

Well as I expected, lots has been happening in the diabetes tech world while I’ve been away working on the African photographic expedition. So this post is a little bit of a catch-up. Ryzodeg At the start of August the Australian PBS was updated to include Novo’s Ryzodeg insulin. Although Novo’s long-acting Tresiba is not …

Catching up with July Read More »

Another “new” insulin for Australia

In April there was big news as Sanofi’s long-acting Toujeo U300 insulin was added to the Pharmaceutical Benefits Scheme (PBS) and thus became accessible to many people. It had received TGA approval some time beforehand and was available under private prescription, but the cost was significant. But at the time I failed to mention another new …

Another “new” insulin for Australia Read More »

Backup insulin pens

For a change I’m not going to write here about the latest insulin pumps, CGMs, and closed-loop systems. This is about insulin pens, and possible compatibility between some models that the manufacturers won’t tell you about. Before I started using an insulin pump, I used injection pens for both my short-acting (“bolus”) insulin and my …

Backup insulin pens Read More »